Thomas Stankovich - 30 Nov 2023 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/ Thomas Stankovich
Issuer symbol
RSLS
Transactions as of
30 Nov 2023
Net transactions value
-$38.78
Form type
4
Filing time
13 Aug 2024, 16:29:13 UTC
Previous filing
08 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Sale $8.97 -39 -0.17% $0.2300 22,910 30 Nov 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale $10.5 -42 -0.18% $0.2500 22,868 31 Dec 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale $7.31 -43 -0.19% $0.1700 22,825 29 Feb 2024 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale $12 -48 -0.21% $0.2500 22,777 31 May 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.